

## Special Issue

# Advanced Research in Stem Cells and Regenerative Medicine

### Message from the Guest Editors

Stem cells are a population of undifferentiated cells characterized by their ability to extensively proliferate (self-renewal) and differentiate into different cell types (potency). Many studies have demonstrated that perinatal derivatives may represent important tools for restoring tissue damage or promoting regeneration and repair of the tissue microenvironment. This Special Issue welcomes all types of manuscripts providing insight on aspects relevant to the use of perinatal derivatives in regenerative medicine. We are interested in a wide range of work, including differentiation to novel cell types or improvement on existing cell types, as well as their preclinical testing. Moreover, we are interested in understanding endogenous processes of tissue repair and homeostasis, stem cells' biology in relation to their therapeutic potential, new approaches in the tracking and imaging of both stem cells and tissues/organs undergoing regeneration, and data from clinical trials of stem-cell-based therapies. Finally, the mechanisms of stem cells' activity, including secretome and extracellular vesicles production, will be highly appreciated.

### Guest Editors

Prof. Dr. Roberta Di Pietro

Department of Medicine and Ageing Sciences, G. d'Annunzio University of Chieti-Pescara, Via dei Vestini 31, 66100 Chieti, Italy

Prof. Dr. Sandra Marmioli

Department of Biomedical, Metabolic and Neuronal Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy

### Deadline for manuscript submissions

closed (31 January 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/116023](https://mdpi.com/si/116023)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).